Pipeline Catalysts Key Focus For Roche’s H1 Update
Swiss Pharma’s Increasing Diversification Also Big Theme
Executive Summary
Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.